- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02772211
D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background MDD is one of the leading causes of disability worldwide [5]. A substantial proportion of patients do not achieve adequate remission despite multiple antidepressant trials and augmentation strategies. TRD is defined as an insufficient response to at least two adequate antidepressant trials. Many of these patients are referred to somatic treatment; e.g. electroconvulsive therapy (ECT), repetitive Transcranial Magnetic Stimulation (rTMS) and Vagal Nerve Stimulation (VNS), all of which can cause side effects, and are not always efficacious.
Ketamine has been safely used for decades for the induction and maintenance of anesthesia and more recently for chronic pain. Ketamine is a noncompetitive, high-affinity antagonist of the NMDA type glutamate receptor, with additional effects on dopamine and μ-opioid receptors. During the last decade, 4 meta analyses summarizing over 22 controlled trials have been published, showing the rapid and impressive effect of ketamine in TRD patients [6-8]. These trials show that a single slow IV ketamine sub-anesthetic dose (0.5 mg/kg) over 40 minutes dramatically improves depressive symptoms. Across studies, a clinically significant antidepressant response was maintained for up to 72 hours in approximately half of the patients; only a minority had relapsed within the first two weeks post-ketamine infusion [9, 10]. aan het Rot et al. [11] showed that repeated IV ketamine infusions prolong the duration of improvement.
D-cycloserine (seromycin) is a broad spectrum antibiotic, in use for over thirty years in the treatment of tuberculosis, DCS functions as a partial agonist at the NMDA-R glycine site, with agonist effects predominating at low dose and antagonist effects at high dose. Low DCS dosages, such as 50-500 mg/d have been implemented in anxiety patients for memory and learning enhancement. Beneficial antidepressant effects have been reported when higher dosages (500-1000 mg/day) were used [3]. DCS regimens in TRD patients suggest that high dose DCS may indeed be beneficial in the treatment of MDD. However, a previous study using a lower dosage (250mg/d) did not show significant difference over placebo [3]. The antidepressant effects of DCS seem to derive from its ability to inhibit NMDA-R function, similarly to ketamine. One recent study demonstrated a beneficial effect of DCS after ketamine infusion in bipolar depression patients [12]. Due to the potential neurotoxicity of ketamine in prolonged administration. Other NMDA antagonist should follow ketamine infusion [13]. Therefore we reason that DCS post-ketamine administration will considerably reduce relapse in TRD patients when compared to placebo.
Study Design
Patients will undergo 6 ketamine infusions within a 3-week period.
Intravenous ketamine will be administrated by a senior anesthesiologist and under the supervision of a senior psychiatrist hence ensuring patient safety. We believe that sub-anesthetic ketamine infusion will be safer and will cause fewer side effects than ECT. The procedure will be explained in detail to each patient, and written consent will be obtained.
After a psychiatric and medical evaluation by a senior psychiatrist and a senior anesthesiologist, patients will be given ketamine infusion added on to their antidepressant therapy. A slow ketamine infusion of 0.5mg/kg over 40 minutes will be given to the patients. Patients will be monitored by the experienced staff which includes a senior anesthesiologist and a nurse as well as a psychiatrist who will be available nearby. All patients will be monitored continuously for heart rate and rhythm and oxygen saturation, and blood pressure will be measured at 10 minutes intervals. Heart rate variability will be measured and analyzed after ketamine treatment. Measurements will be performed during the ketamine infusion at baseline, after 3 and 6 treatments. Depressive symptoms will be measured using Montgomery Asberg Depression Scale (MADRS). In addition Clinical Global Severity Scale (CGI-S) and Clinical Global Improvement (CGI-I) will be performed 2 hours after treatment. In many cases, patients with depression also suffer from alexithymia: inappropriate identification of emotions. Alexithymia will be measured at baseline after 3 and 6 treatments. Ketamine infusion will be stopped in cases of a 20% or above increase in blood pressure or in heart rate over baseline values and/ or an acute dissociative state.
Patients will be discharged to their homes at least three hours from end of infusion. Due to the potential effect of ketamine each patient will need to be escorted to and from the hospital by a family member or a friend.
For patients who will meet response criteria (MADRS≥25%) after 6 ketamine infusions, ketamine administration (weeks 1-3: days 1-21) will be stopped and patients will start receiving DCS or placebo titrated slowly up to 1000mg/d over the next 8 weeks [2] in the following manner:
- Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.
- Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day
- Week 7: Day 43-49 - 750mg/d, three pills per day
- Weeks 8-11: Days 50-77 - 1000mg/d four pills per day
- Pyridoxine 200-300mg/d will be prescribed for all patients at the beginning of the study.
- Patients who did not improve after 6 ketamine treatments will be removed from the study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Revital Amiaz, MD
- Phone Number: +972-542378757
- Email: revital.amiaz@sheba.health.gov.il
Study Locations
-
-
-
Ramat-Gan, Israel
- Psychiatry Clinic - Sheba Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged 18-75 meeting DSM-V criteria for moderate-severe depression (MADRS≥25), who did not respond to two adequate antidepressant courses of treatment. Subjects will be required to continue on a stable dose of any psychotropic medication they are taking, for 8 weeks prior to ketamine infusion. Participants who respond to ketamine (reduction of 25% in symptoms) would be invited to participate in a second stage of the experiment, in which participants would consume DCS for 8 weeks (weeks 4-11).
Exclusion Criteria:
- Patients will be excluded if they have current or history of psychotic or dissociative symptoms, or severe personality disorder with psychosis or dissociative symptoms. Additional exclusion criteria will be a lifetime history of psychotic mania, a substance abuse or use of alcohol. Medical exclusion criteria will include - uncontrolled elevated blood pressure, non-sinus rhythm, unstable ischemic heart disease, uncorrected hyper thyroidism, and for women, pregnancy or the initiation of female hormonal treatment <3 months. Before ketamine treatment women of childbearing age will be required to use a medical accepted contraceptive or abstain from sexual activity. In addition patients will be excluded if they suffer from chronic renal failure, epilepsy, organic brain disorder or neurological or an unstable medical condition. Due to neurotoxicity and convulsions, patients will be prohibited to consume alcohol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: D-cycloserine
Participants in this group would receive 6 infusions of ketamine.
Participants who demonstrate symptoms reduction following ketamine infusions would receive oral D-cycloserine, titrated slowly up to 1000mg/d over the next 8 weeks.
|
Patients will undergo 6 ketamine infusions within a 3-week period. Intravenous ketamine will be administrated by a senior anesthesiologist and under the supervision of a senior psychiatrist hence ensuring patient safety. The procedure will be explained in detail to each patient, and written consent will be obtained. After a psychiatric and medical evaluation by a senior psychiatrist and a senior anesthesiologist, patients will be given ketamine infusion added on to their antidepressant therapy. A slow ketamine infusion of 0.5mg/kg over 40 minutes will be given to the patients. Patients will be monitored by the experienced staff which includes a senior anesthesiologist and a nurse as well as a psychiatrist who will be available nearby. All patients will be monitored continuously for heart rate and rhythm and oxygen saturation, and blood pressure will be measured at 10 minutes intervals. Following completion of Ketamine infusions. patients in the experimental group will start receiving D-cycloserine pills titrated slowly up to 1000mg/d over the next 8 weeks [2] in the following manner:
Other Names:
|
Placebo Comparator: Placebo
Participants in this group would receive 6 infusions of ketamine.
Participants who demonstrate symptoms reduction following ketamine infusions would receive oral Placebo pills, titrated slowly up to 1000mg/d over the next 8 weeks.
|
Patients will undergo 6 ketamine infusions within a 3-week period. Intravenous ketamine will be administrated by a senior anesthesiologist and under the supervision of a senior psychiatrist hence ensuring patient safety. The procedure will be explained in detail to each patient, and written consent will be obtained. After a psychiatric and medical evaluation by a senior psychiatrist and a senior anesthesiologist, patients will be given ketamine infusion added on to their antidepressant therapy. A slow ketamine infusion of 0.5mg/kg over 40 minutes will be given to the patients. Patients will be monitored by the experienced staff which includes a senior anesthesiologist and a nurse as well as a psychiatrist who will be available nearby. All patients will be monitored continuously for heart rate and rhythm and oxygen saturation, and blood pressure will be measured at 10 minutes intervals. Following completion of Ketamine infusions. patients in the experimental group will start receiving placebo titrated slowly up to 1000mg/d over the next 8 weeks [2] in the following manner:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Montgomery Asberg Depression Scale (MADRS)
Time Frame: screening criteria, after third ketamine infusions
|
A diagnostic questionnaire, measuring the severity of depressive episodes.
|
screening criteria, after third ketamine infusions
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hamilton depression Rating Scale
Time Frame: Up to ten days pre first ketamine administration, after third ketamine infusion, after sixth ketamine infusion, week 7, week 11, 2 months after study completion
|
A diagnostic questionnaire, measuring the severity of depressive episodes.
|
Up to ten days pre first ketamine administration, after third ketamine infusion, after sixth ketamine infusion, week 7, week 11, 2 months after study completion
|
Clinical Global Severity Scale
Time Frame: Up to ten days pre first ketamine administration, after third ketamine infusion, after sixth ketamine infusion, week 7, week 11, 2 months after study completion
|
A questionnaire, measuring the current global state of a person
|
Up to ten days pre first ketamine administration, after third ketamine infusion, after sixth ketamine infusion, week 7, week 11, 2 months after study completion
|
Clinical Global Improvement
Time Frame: after third ketamine infusion, after sixth ketamine infusion, week 7, week 11, 2 months after study completion
|
A questionnaire, measuring the improvement in clinical symptoms
|
after third ketamine infusion, after sixth ketamine infusion, week 7, week 11, 2 months after study completion
|
Hamilton Anxiety Scale
Time Frame: Up to ten days pre first ketamine administration, after third ketamine infusion, after sixth ketamine infusion, week 7, week 11, 2 months after study completion
|
Up to ten days pre first ketamine administration, after third ketamine infusion, after sixth ketamine infusion, week 7, week 11, 2 months after study completion
|
|
Toronto Alexithymia Scale
Time Frame: Up to ten days pre first ketamine administration, after third ketamine infusion, after sixth ketamine infusion, week 7, week 11, 2 months after study completion
|
Up to ten days pre first ketamine administration, after third ketamine infusion, after sixth ketamine infusion, week 7, week 11, 2 months after study completion
|
|
N-Back test
Time Frame: Up to ten days pre first ketamine administration, after third ketamine infusion, after sixth ketamine infusion, week 7, week 11, 2 months after study completion
|
computerized tasks featuring neutral stimuli
|
Up to ten days pre first ketamine administration, after third ketamine infusion, after sixth ketamine infusion, week 7, week 11, 2 months after study completion
|
Verbal Fluency test
Time Frame: Up to ten days pre first ketamine administration, after third ketamine infusion, after sixth ketamine infusion, week 7, week 11, 2 months after study completion
|
computerized tasks featuring neutral stimuli
|
Up to ten days pre first ketamine administration, after third ketamine infusion, after sixth ketamine infusion, week 7, week 11, 2 months after study completion
|
Stop signal test
Time Frame: Up to ten days pre first ketamine administration, after third ketamine infusion, after sixth ketamine infusion, week 7, week 11, 2 months after study completion
|
computerized tasks featuring neutral stimuli
|
Up to ten days pre first ketamine administration, after third ketamine infusion, after sixth ketamine infusion, week 7, week 11, 2 months after study completion
|
ANTI
Time Frame: Up to ten days pre first ketamine administration, after third ketamine infusion, after sixth ketamine infusion, week 7, week 11, 2 months after study completion
|
computerized tasks featuring neutral stimuli
|
Up to ten days pre first ketamine administration, after third ketamine infusion, after sixth ketamine infusion, week 7, week 11, 2 months after study completion
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Depressive Disorder, Treatment-Resistant
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Antimetabolites
- Anti-Bacterial Agents
- Antitubercular Agents
- Antibiotics, Antitubercular
- Anti-Infective Agents, Urinary
- Renal Agents
- Ketamine
- Cycloserine
Other Study ID Numbers
- 2853-15-SMC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Treatment Resistant Depression
-
Changping LaboratoryBeijing HuiLongGuan HospitalRecruitingTreatment-Resistant DepressionChina
-
Central Institute of Mental Health, MannheimCharite University, Berlin, Germany; German Federal Ministry of Education and... and other collaboratorsActive, not recruitingTreatment-resistant DepressionGermany
-
Janssen Research & Development, LLCCompletedTreatment-resistant DepressionUnited States, Australia, France, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Poland, Bulgaria, Malaysia, South Africa, Turkey, Finland, Korea, Republic of, Brazil, Austria, Sweden, Lithuania
-
Janssen Research & Development, LLCCompletedTreatment-resistant DepressionUnited States, France, Belgium, Mexico, Canada, Brazil, Estonia, Hungary, Slovakia
-
University of OttawaCanadian Institutes of Health Research (CIHR)Completed
-
GH Research Ireland LimitedRecruitingTreatment-resistant DepressionIreland, Czechia
-
First Affiliated Hospital of Zhejiang UniversityRecruitingTreatment-resistant DepressionChina
-
University Hospital FreiburgBoston Scientific CorporationRecruitingTreatment-resistant DepressionGermany, France
-
Janssen Research & Development, LLCCompletedTreatment-resistant DepressionUnited States, Poland, Germany, Spain, Czechia
-
Millennium Pharmaceuticals, Inc.WithdrawnTreatment-Resistant Depression
Clinical Trials on Ketamine
-
Grace Lim, MD, MSNational Institute of Mental Health (NIMH)RecruitingPain, Postoperative | Depression, PostpartumUnited States
-
Ullevaal University HospitalUniversity of OsloCompleted
-
Assistance Publique - Hôpitaux de ParisCompletedArthroplasty, Replacement, HipFrance
-
Assiut UniversityCompletedKetamine Causing Adverse Effects in Therapeutic UseEgypt
-
Lawson Health Research InstituteUnknownBone Fractures | Dislocations
-
Eye & ENT Hospital of Fudan UniversityCompletedPain, Procedural | Emotions | Separation AnxietyChina
-
The University of Texas Health Science Center,...TerminatedPost Partum DepressionUnited States
-
Lotus Clinical Research, LLCiX Biopharma Ltd.Completed
-
Antonios LikourezosCompleted